218 related articles for article (PubMed ID: 30135687)
21. Anti-APOBEC3G activity of HIV-1 Vif protein is attenuated in elite controllers.
Kikuchi T; Iwabu Y; Tada T; Kawana-Tachikawa A; Koga M; Hosoya N; Nomura S; Brumme ZL; Jessen H; Pereyra F; Trocha A; Walker BD; Iwamoto A; Tokunaga K; Miura T
J Virol; 2015 May; 89(9):4992-5001. PubMed ID: 25717111
[TBL] [Abstract][Full Text] [Related]
22. Expression analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and tetherin in a Senegalese cohort of HIV-1-exposed seronegative individuals.
Mous K; Jennes W; Camara M; Seydi M; Daneau G; Mboup S; Kestens L; Van Ostade X
PLoS One; 2012; 7(3):e33934. PubMed ID: 22479480
[TBL] [Abstract][Full Text] [Related]
23. A naturally occurring Vif mutant (I107T) attenuates anti-APOBEC3G activity and HIV-1 replication.
Peng J; Ao Z; Matthews C; Wang X; Ramdahin S; Chen X; Li J; Chen L; He J; Ball B; Fowke K; Plummer F; Embree J; Yao X
J Mol Biol; 2013 Aug; 425(16):2840-52. PubMed ID: 23707381
[TBL] [Abstract][Full Text] [Related]
24. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
25. APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression.
Vázquez-Pérez JA; Ormsby CE; Hernández-Juan R; Torres KJ; Reyes-Terán G
Retrovirology; 2009 Mar; 6():23. PubMed ID: 19254362
[TBL] [Abstract][Full Text] [Related]
26. The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.
Sharma S; Patnaik SK; Taggart RT; Baysal BE
Sci Rep; 2016 Dec; 6():39100. PubMed ID: 27974822
[TBL] [Abstract][Full Text] [Related]
27. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
28. Role of APOBEC3 proteins in proteasome inhibitor-mediated reactivation of latent HIV-1 viruses.
Timilsina U; Ghimire D; Sharma S; Gaur R
J Gen Virol; 2019 Mar; 100(3):523-532. PubMed ID: 30566069
[TBL] [Abstract][Full Text] [Related]
29. Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.
Pillai SK; Abdel-Mohsen M; Guatelli J; Skasko M; Monto A; Fujimoto K; Yukl S; Greene WC; Kovari H; Rauch A; Fellay J; Battegay M; Hirschel B; Witteck A; Bernasconi E; Ledergerber B; Günthard HF; Wong JK;
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3035-40. PubMed ID: 22315404
[TBL] [Abstract][Full Text] [Related]
30. IFN-α induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells.
Mohanram V; Sköld AE; Bächle SM; Pathak SK; Spetz AL
J Immunol; 2013 Apr; 190(7):3346-53. PubMed ID: 23427247
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
32. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
Rose KM; Marin M; Kozak SL; Kabat D
J Biol Chem; 2004 Oct; 279(40):41744-9. PubMed ID: 15297452
[TBL] [Abstract][Full Text] [Related]
33. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
[TBL] [Abstract][Full Text] [Related]
34. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors.
Gandhi SK; Siliciano JD; Bailey JR; Siliciano RF; Blankson JN
J Virol; 2008 Mar; 82(6):3125-30. PubMed ID: 18077705
[TBL] [Abstract][Full Text] [Related]
35. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity.
Peng G; Lei KJ; Jin W; Greenwell-Wild T; Wahl SM
J Exp Med; 2006 Jan; 203(1):41-6. PubMed ID: 16418394
[TBL] [Abstract][Full Text] [Related]
36. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Berenguer J; González J; Ribera E; Domingo P; Santos J; Miralles P; Angels Ribas M; Asensi V; Gimeno JL; Pérez-Molina JA; Terrón JA; Santamaría JM; Pedrol E;
Clin Infect Dis; 2008 Oct; 47(8):1083-92. PubMed ID: 18781872
[TBL] [Abstract][Full Text] [Related]
37. Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F.
Ulenga NK; Sarr AD; Thakore-Meloni S; Sankalé JL; Eisen G; Kanki PJ
J Infect Dis; 2008 Aug; 198(4):486-92. PubMed ID: 18598197
[TBL] [Abstract][Full Text] [Related]
38. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
39. Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex.
Zhang S; Zhong L; Chen B; Pan T; Zhang X; Liang L; Li Q; Zhang Z; Chen H; Zhou J; Luo H; Zhang H; Bai C
Antiviral Res; 2015 Oct; 122():20-7. PubMed ID: 26241003
[TBL] [Abstract][Full Text] [Related]
40. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection.
Kim EY; Lorenzo-Redondo R; Little SJ; Chung YS; Phalora PK; Maljkovic Berry I; Archer J; Penugonda S; Fischer W; Richman DD; Bhattacharya T; Malim MH; Wolinsky SM
PLoS Pathog; 2014 Jul; 10(7):e1004281. PubMed ID: 25080100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
